WVE 008
Alternative Names: PNPLA3 GalNAc-AIMer -WaVe life Sciences; PNPLA3 targeted GalNAc-AIMer - WaVe life Sciences; WVE-008Latest Information Update: 31 Aug 2026
At a glance
- Originator WaVe life Sciences
- Class Amines; Amino sugars; Drug conjugates; Hepatoprotectants; Oligonucleotides; Pyrrolidines
- Mechanism of Action Adiponutrin expression modulators; RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 30 Jul 2026 Pharmacodynamics data from a preclinical trial in Liver disorder released by WaVe life Sciences
- 30 Oct 2025 Wave Life Sciences announces intention to submit clinical trial application (CTA) for Liver disorders in 2026
- 30 Oct 2025 Wave Life Sciences plans a clinical trial for Liver disorders in 2026